FDA lifts par­tial hold on ADC, clear­ing way for a 2021 read­out and two po­ten­tial near-term ap­provals

In throw­ing $267 mil­lion and a mul­ti-bil­lion dol­lar val­u­a­tion at ADC Ther­a­peu­tics for their May IPO, in­vestors were bet­ting that the par­tial hold the FDA had just placed on their sec­ond lead drug would prove im­ma­te­r­i­al. Time, it ap­pears, has proven them right.

The FDA has lift­ed the par­tial hold, ADC said this morn­ing. The move clears the way for an an­tic­i­pat­ed 2021 read­out from their sec­ond piv­otal study, a Phase II tri­al test­ing their ex­per­i­men­tal an­ti­body drug con­ju­gate cami­dan­lum­ab tesirine, or Ca­mi, in Hodgkin’s lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER